Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31184150 | 1.00 | PSMD14 (0.41) | PSMD14COPS5DHODHNFE2L2TRPV4 | |
| SCHEMBL18726968 | 0.82 | SCN9A (0.43) | PSMD14COPS5NFE2L2 | |
| SCHEMBL15473322 | 0.77 | CBFB (0.42) | DHODHP2RY1TLR7 | |
| SCHEMBL30785493 | 0.75 | TLR7 (0.47) | DHODHP2RY1TYK2TLR7ALDH1A1 | |
| SCHEMBL21384474 | 0.75 | TLR7 (0.37) | DHODHTLR7ALDH1A1 | |
| SCHEMBL2301288 | 0.75 | KDM4E (0.38) | DHODHTYK2TLR7ALDH1A1MAPT | |
| SCHEMBL18320509 | 0.75 | TLR7 (0.47) | DHODHP2RY1TYK2TLR7ALDH1A1 | |
| SCHEMBL16887439 | 0.75 | NOS3 (0.43) | DHODH | |
| SCHEMBL30319978 | 0.75 | KDM4E (0.38) | DHODHTYK2TLR7ALDH1A1MAPT | |
| SCHEMBL25154251 | 0.75 | P2RY1 (0.47) | DHODHTRPV4P2RY1P2RY2P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112625028-A | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-107922388-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-107787323-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2020-09-01 | — | — | CN | disclosed |
| EP-3310771-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-07-22 | — | — | EP | disclosed |
| EP-3310774-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-10308660-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-06-04 | — | — | US | disclosed |
| US-10308660-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-06-04 | — | — | US | disclosed |
| US-10287266-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-05-14 | — | — | US | disclosed |
| US-10287266-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-05-14 | — | — | US | disclosed |
| US-20180251471-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-09-06 | — | — | US | disclosed |
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-07-05 | — | — | US | disclosed |
| EP-3310771-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2018-04-25 | — | — | EP | disclosed |
| EP-3310774-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203405-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203406-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203405-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203406-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251471-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN3, PTPN1, PTPN2 | PSMD14 3481/4885COPS5 731/4885DHODH 4418/4885 |
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN2 | PSMD14 3590/4885COPS5 688/4885DHODH 4361/4885 |
| US-10308660-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN3, PTPN1, PTPN2 | PSMD14 3481/4885COPS5 731/4885DHODH 4418/4885 |
| US-10287266-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN3, PTPN2 | PSMD14 3541/4885COPS5 729/4885DHODH 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.